The effect of omega-3 supplementation on glycemic indices and lipid profile in type 2 diabetic patients with non-alcoholic fatty liver disease: A double-blind,randomized,clinical trial
Restricted accessResearch articleFirst published online June 14, 2019
The effect of omega-3 supplementation on glycemic indices and lipid profile in type 2 diabetic patients with non-alcoholic fatty liver disease: A double-blind,randomized,clinical trial
Serum phospholipid omega-3 fatty acid levels in patients suffering from both type 2 diabetes (T2DM) and non-alcoholic fatty liver (NAFLD) are lower than in their healthy counterparts. Omega-3 supplementation can be effective in controlling glycemic indices in T2DM, and in improving lipid profiles in T2DM and NAFLD as well. The aim of this study was to evaluate the effects of omega-3 fatty acid supplementation on glycemic control and lipid profile in patients with T2DM and NAFLD.
METHODS:
In this randomized double-blind placebo-controlled clinical trial, 60 patients with T2DM and NAFLD were enrolled. The participants were randomly divided into two groups. The omega-3 group (OG) received capsules containing omega-3 fatty acids (2g/d), and the placebo group (PG) received placebo capsules (2g/d) during a12 week period. Dietary intake was assessed with 24-hour dietary recalls. Fasting blood samples and anthropometric measurements were collected at the baseline and after 12 weeks. Serum levels of glycemic indices (fasting blood glucose (FBG) levels, glycosylated hemoglobin (HbA1c)) and lipid profile (levels of triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c) and high density lipoprotein cholesterol (HDL-c)) were measured.
RESULTS:
Fifty-six patients completed the study. Paired t-test revealed no significant differences in the baseline measurements between the two groups. At the end of the study compared with the PG, the OG had a significant reduction in serum TG levels. However, there was no significant effect of omega-3 supplementation on the other parameters: the mean FBG or HbA1c concentration, neither on TC, LDL-c and HDL-c levels.
CONCLUSION:
Two grams per day of omega-3 supplementation after 12 weeks led to a significant reduction in serum TG levels in patients with T2DM and NAFLD. However, no significant effects were observed on FBG, HbA1c, TC, LDL-c, and HDL-c levels.
SanyalAJ, Chalasani.;1;N, KowdleyKV, McCulloughA, DiehlAM, BassNM, et al.Pioglitazone, VitaminE, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2010;362(18):1675–85. PubMed PMID: 20427778.
2.
McCulloughAJ.;1; Update on nonalcoholic fatty liver disease. Journal of clinical gastroenterology. 2002 Mar;34(3):255–62. PubMed PMID: 11873108. Epub 2002/03/02. eng.
3.
ParkerHM, JohnsonNA, BurdonCA, CohnJS, O'ConnorHT, GeorgeJ.;1; Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of hepatology. 2012 Apr;56(4):944–51. PubMed PMID: 22023985. Epub 2011/10/26. eng.
4.
JumpDB, LytleKA, DepnerCM, TripathyS.;1; Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacology and Therapeutics. 2017;181:108–25.
5.
BellentaniS, MarinoM.;1; Epidemiology and natural history of non-alcoholicfatty liver disease (NAFLD). Ann Hepatol. 2009;8(Suppl 1):S4–S8.
6.
AnguloP.;1; Nonalcoholic fatty liver disease. New England Journal of Medicine. 2002;346(16):1221–31.
7.
YuL, YuanM, WangL.;1; The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs. Pakistan journal of medical sciences. 2017 Jul-Aug;33(4):1022–8. PubMed PMID: 29067086. Pubmed Central PMCID: Pmc5648933. Epub 2017/10/27. eng.
8.
SimopoulosA.;1; Human requirement for N-3 polyunsaturated fatty acids. Poultry science. 2000;79(7):961–70.
9.
SimopoulosAP.;1; Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet.
Healthy agriculture, healthy nutrition, healthy people. 102:Karger Publishers; 2011. p. 10–21.
10.
Araya.;1; J, RodrigoR, VidelaLA, ThielemannL, OrellanaM, PettinelliP, et al. Increase in long-chain polyunsaturated fatty acid n–6/n–3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clinical science. 2004;106(6):635–43.
11.
CrochemoreIC, SouzaAF, de SouzaAC, Rosado.;1; EL.omega-3 polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition. 2012 Aug;27(4):553–60. PubMed PMID: 22661243. Epub 2012/06/05. eng.
12.
WalkerKZ, O’DeaK, GomezM, GirgisS, ColagiuriR.;1; Diet and exercise in the prevention of diabetes. Journal of human nutrition and dietetics : the official journal of the British Dietetic Association. 2010 Aug;23(4):344–52. PubMed PMID: 20337844. Epub 2010/03/27. eng.
13.
SantosRD.III;1; Diretrizes brasileiras sobre dislipidemias e diretriz de preveçäo da aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arquivos Brasileiros de Cardiologia. 2001;77:1–48.
14.
Hartweg.;1; J, PereraR, MontoriV, DinneenS, NeilHA, FarmerA.Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2008 Jan 23(1):Cd003205. PubMed PMID: 18254017. Epub 2008/02/07. eng.
15.
AlvinC.Powers.DLKasper BrounwalE, FauciAS.;1; Harrisons Principle of Internal Medicine. New York: Mc Graw Hill Publishers; 2005.
16.
AtanN, KoushkiM, MotedayenM, DoustiM, SayehmiriF, VafaeeR, et al.;1; Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology and hepatology from bed to bench. 2017;10((Suppl1)):p.S1.
17.
ChiuCY, GomolkaB, DierkesC, HuangNR, SchroederM, PurschkeM, et al.;1; Omega-6 docosapentaenoic acid-derivedresolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis. Inflammation research : official journal of the European Histamine Research Society[et al]. 2012 Sep;61(9):967–76. PubMed PMID: 22618200. Epub 2012/05/24. eng.
18.
ForoughiM, AzadbakhtL.Omega-3 Fatty Acids and Non-Alcoholic Fatty Liver Disease.;1;Health system research. 2013;9(3):2590268.
19.
Zelber-SagiS, RatziuV, OrenR.;1; Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World journal of gastroenterology. 2011Aug 7;17(29):3377–89. PubMed PMID: 21876630. Pubmed Central PMCID: Pmc3160564. Epub 2011/08/31. eng.
20.
ArendtBM, MohammedSS, AghdassiE, PrayitnoNR, MaDW, NguyenA, et al.;1; Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. The Journal of nutrition. 2009;139(4):691–5.
21.
DepnerCM, PhilbrickKA, JumpDB.;1; Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr-/- mouse model of western diet-induced nonalcoholic steatohepatitis. The Journal of nutrition. 2013;143(3):315–23.
22.
DepnerCM, TraberMG, BobeG, KensickiE, BohrenKM, MilneG, et al.;1; A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/-mice. PLoS One. 2013;8(12):e83756.
23.
BorengasserSJ, RectorRS, UptergroveGM, MorrisEM, PerfieldJW2nd,;1;, BoothFW, et al. Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of Hepatic Steatosis in Hyperphagic OLETF Rats. Journal of nutrition and metabolism. 2012;2012:268–680. PubMed PMID: 21918718. Pubmed Central PMCID: Pmc3171760. Epub 2011/09/16. eng.
24.
SpadaroL, MaglioccoO, SpampinatoD, PiroS, OliveriC, AlagonaC, et al.;1; Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2008Mar;40(3):194–9. PubMed PMID: 18054848. Epub 2007/12/07. eng.
25.
SantosAC, EbrahimS, BarrosH.;1; Gender, socio-economic status and metabolic syndrome in middle-aged and old adults. BMC Public Health. 2008;8(1):62.
26.
AlavianSM, Mohammad-AlizadehAH, Esna-AshariF, ArdalanG, HajarizadehB.;1; Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver international. 2009;29(2):159–63.
27.
Rast maneshR, TalebanAF, KimiagarM, MehrabiY.;1; Effect of omega-3 fatty acids on inflammatory, insulin sensitivity and metabolic control in type 2 diabetic patients. Contemporary clinical trials. 2004Mar;37(2):281–7. PubMed PMID: 24556343. Epub 2004. Per.
28.
LankaraniKB, GhaffarpasandF, MahmoodiM, LotfiM, ZamiriN, HeydariST, et al.;1; Non alcoholic fatty liver disease in southern Iran: a population based study. Hepatitis monthly. 2013May;13(5):e9248. PubMed PMID: 23922564. Pubmed Central PMCID: Pmc3734894. Epub 2013/08/08. eng.
29.
KaushikM, MozaffarianD, SpiegelmanD, MansonJE, WillettWC, HuFB.;1; Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. The American journal of clinical nutrition. 2009Sep;90(3):613–20. PubMed PMID: 19625683. Pubmed Central PMCID: Pmc2728645. Epub 2009/07/25. eng.
30.
LouD-j, ZhuQ-q, SiX-w, GuanL-l, YouQ-y, YuZ-m, et al.;1; Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease. Journal of Diabetes and its Complications. 2014;28(5):711–4.
31.
DasarathyS, Dasarathy.;1; J, KhiyamiA, YerianL, HawkinsC, SargentR, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. Journal of clinical gastroenterology. 2015Feb;49(2):137–44. PubMed PMID: 24583757. Pubmed Central PMCID: Pmc4147029. Epub 2014/03/04. eng.
32.
HeXX, WuXL, ChenRP, ChenC, LiuXG, WuBJ, et al.;1; Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0162368. PubMed PMID: 27711128. Pubmed Central PMCID: Pmc5053538. Epub 2016/10/07. eng.
33.
ScorlettiE, BhatiaL, McCormickKG, CloughGF, NashK, HodsonL, et al.;1; Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology (Baltimore, Md). 2014Oct;60(4):1211–21. PubMed PMID: 25043514. Epub 2014/07/22. eng.
34.
ZhuFS, LiuS, ChenXM, HuangZG, ZhangDW.;1; Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World journal of gastroenterology. 2008Nov 7;14(41):6395–400. PubMed PMID: 19009658. Pubmed Central PMCID: Pmc2766124. Epub 2008/11/15. eng.
35.
ChenC, YuX, ShaoS.;1; Effects of Omega-3 Fatty Acid Supplementation on Glucose Control and Lipid Levels in Type 2 Diabetes: A Meta-Analysis. PLoS One. 2015;10(10):e0139565. PubMed PMID: 26431431. Pubmed Central PMCID: Pmc4591987. Epub 2015/10/03. eng.
36.
JeppesenC, SchillerK, SchulzeMB.;1; Omega-3 and omega-6 fatty acids and type 2 diabetes. Current diabetes reports. 2013Apr;13(2):279–88. PubMed PMID: 23325534. Epub 2013/01/18. eng.
37.
ToorangF, DjazayeryA, DjalaliM.;1; Effects of Omega-3 Fatty Acids Supplement on Antioxidant Enzymes Activity in Type 2 Diabetic Patients. Iranian journal of public health. 2016Mar;45(3):340–5. PubMed PMID: 27141496. Pubmed Central PMCID: Pmc4851748. Epub 2016/05/04. eng.
38.
Delarue.;1; J, LeFollC, CorporeauC, LucasD.N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?Reproduction Nutrition Development. 2004;44(3):289–99.
